Get the Stockscreener App
0.53
27.89%
-0.205
After Hours:
.53
Avenue Therapeutics Inc stock is traded at $0.53, with a volume of 8,673.
It is down -27.89% in the last 24 hours and down -27.89% over the past month.
See More
Previous Close:
$0.735
Open:
$0.5502
24h Volume:
8,673
Relative Volume:
13.06
Market Cap:
$N/A
Revenue:
$1.40M
Net Income/Loss:
$-2.95M
P/E Ratio:
-0.5547
EPS:
-0.9554
Net Cash Flow:
$-1.83M
1W Performance:
-27.89%
1M Performance:
-27.89%
6M Performance:
-27.89%
1Y Performance:
-96.88%
1-Day Range:
$0.53
$0.5502
1-Week Range:
$0.53
$0.5502
52-Week Range:
$0.5231
$0.735
Avenue Therapeutics Inc Stock (ATXI) Company Profile
Name
Avenue Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare ATXI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATXI
Avenue Therapeutics Inc
|
0.53 | 0 | 1.40M | -2.95M | -1.83M | -0.9554 |
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.17 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Avenue Therapeutics Inc Stock (ATXI) Latest News
MSN Money - MSN
AVENUE THERAPEUTICS, INC. 1Q 2026: Net loss $0.7M, Revenue $0— 10-Q Summary - TradingView
Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Avenue Therapeutics (OTC: ATXI) cuts Q1 loss but warns on going concern - Stock Titan
Board elections and auditor vote at MiNK Therapeutics (NASDAQ: INKT) - Stock Titan
Executive pay, major holders and votes in Foghorn (NASDAQ: FHTX) 2026 proxy - Stock Titan
Executive pay and audits headline Monte Rosa (NASDAQ: GLUE) 2026 proxy - Stock Titan
Abeona Therapeutics (NASDAQ: ABEO) sets 2026 virtual meeting on directors, pay and equity plan - Stock Titan
Intellia Therapeutics Announces Proposed Public Offering of Common Stock - Intellia Therapeutics
Form S-1/A Hemab Therapeutics Holdi - StreetInsider
Coya Therapeutics (NASDAQ:COYA) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Abeona Therapeutics (NASDAQ: ABEO) asks shareholders to approve 3.1M extra equity shares - Stock Titan
Perspective Therapeutics (NASDAQ: CATX) sets 2026 director, auditor and pay vote - Stock Titan
Visa Inc. $V is Douglas Lane & Associates LLC’s 10th Largest Position - Defense World
Form 10-KAnnual report [Section 13 and 15(d), not S-K Item 405] - ADVFN
Stock List: Research Stocks from Around the World - GuruFocus
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Fortress Biotech (NASDAQ: FBIO) turns 2025 profit with $205M PRV sale and new royalties - Stock Titan
フォートレス・バイオテック、2025年度財務実績及び直近の企業ハイライトを報告 - Moomoo
Avenue Therapeutics Focuses on Neurologic Disease Therapies with ATX-04 and IV Tramadol as Key Product Candidates in 2026 - Minichart
ATXI: 2025 net loss narrowed to $2.9M as focus shifts to ATX-04 and IV tramadol amid funding challenges - TradingView
Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Avenue Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Maze Therapeutics (NASDAQ:MAZE) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million - The Manila Times
Turn Therapeutics secures up to $25M in financing from Avenue Capital Group - MSN
Turn Therapeutics Secures Up to $25 Million Financing from Avenue Capital to Advance Atopic Dermatitis and Onychomycosis Programs - Minichart
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group - PharmiWeb.com
Turn Therapeutics Secures Up To $25 Million Term Loan Facility From Avenue Venture Opportunities - TradingView — Track All Markets
Turn Therapeutics (Nasdaq: TTRX) secures up to $25M loan facility - Stock Titan
Turn Therapeutics Inc. Enters into Loan and Security Agreement for Up to $25 Million Growth Capital Loan Facility with Avenue Venture Opportunities Fund Ii, L.P - marketscreener.com
Turn Therapeutics secures $25M loan facility from Avenue Capital - Investing.com
Turn Therapeutics, Inc. Secures Up to $25 Million in Financing from Avenue Capital Group - marketscreener.com
Turn Therapeutics Inc. announced that it expects to receive $25 million in funding from Avenue Capital Management II, L.P. - MarketScreener
Fortress Biotech (FBIO) Executive Vice Chairman granted 475,424 restricted shares - Stock Titan
ATXI SEC FilingsAvenue Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Neurology stocks rebound in 2025 after midyear slump - BioWorld MedTech
TG Therapeutics, Inc.Common Stock (NQ: TGTX - The Chronicle-Journal
Tangible book value per share of Avenue Therapeutics, Inc. – LS:A40BWJ - TradingView
Net current asset value per share of Avenue Therapeutics, Inc. – LS:A40BWJ - TradingView
Intellia Therapeutics (NASDAQ:NTLA) Upgraded at Wall Street Zen - MarketBeat
Deal Watch: Esperion Augments Cardiovascular Franchise Via Corstasis Buyout - Citeline News & Insights
Halozyme Therapeutics, Inc. $HALO Shares Sold by Cary Street Partners Financial LLC - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
ATXI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
PKTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Avenue Therapeutics to develop add-on Pompe disease treatment - Pompe Disease News
Palvella Therapeutics Announces Proposed Public Offering - GlobeNewswire
Avenue Therapeutics licenses ATX-04 for Pompe disease treatment By Investing.com - Investing.com Australia
Avenue Therapeutics Licenses ATX-04 for Pompe Disease - TipRanks
Avenue Therapeutics (OTC: ATXI) licenses ATX-04 Pompe therapy from Duke - Stock Titan
Avenue Therapeutics Inc Stock (ATXI) Financials Data
Revenue
Net Income
Cash Flow
EPS
11.97%
3.48%
Cap:
|
Volume (24h):